HCP Connect Clinical Author
Dr. Simran Kohli
Infectious Diseases
Specialty
Infectious Diseases
Clinical Updates
14
Experience
4 Years
Author Biography
About Dr. Simran Kohli
Dr. Simran Kohli is an infectious-diseases physician with 4 years of clinical experience. She earned a DM in Infectious Diseases after an MD in General Medicine, focusing on antimicrobial stewardship and HIV care. She follows the challenge of antimicrobial resistance with particular concern. Her writing keeps clinicians updated on emerging infections and therapies.
Published Work
Recent Clinical Updates
14 articles
Infectious Disease
FDA Expands AREXVY to Adults 18–59 at Increased RSV Risk
AREXVY FDA expands indication to adults 18–59 at increased risk for RSV LRTD; prior adult data showed 82.6% LRTD risk reduction and 94.1% reduction for severe LRTD.
Infectious Disease
FDA Approves zoliflodacin for Uncomplicated Urogenital Gonorrhea: 90.9% Microbiologic Cure
zoliflodacin uncomplicated urogenital gonorrhea: FDA approved Dec 12, 2025; single 3 g oral dose; microbiological cure 90.9% vs 96.2% in Trial 1.
Infectious Disease
FDA Approves doravirine/islatravir for Virologically Suppressed HIV‑1: 1% ≥50 copies/mL
FDA approves doravirine/islatravir (IDVYNSO) for virologically suppressed HIV‑1 in adults; Week 48 trials showed 1% with HIV‑1 RNA ≥50 copies/mL in IDVYNSO arms.
Infectious Disease
REVIVE: Fluvoxamine Reduces Fatigue Severity (−0.43 FSS) vs Placebo
Fluvoxamine long COVID fatigue: REVIVE trial found −0.43 mean FSS reduction vs placebo at day 60; sustained at day 90 (NCT06128967).
Infectious Disease
Nirmatrelvir/Ritonavir Cuts Hospitalization Risk 89% in EPIC-HR
Nirmatrelvir/ritonavir (PAXLOVID) reduced Covid-19 hospitalization/death risk by ~89% in EPIC-HR. Key efficacy, safety, dosing, and prescribing considerations for clinicians.
Infectious Disease
FDA Approves zoliflodacin for Gonorrhea: 90.9% Cure Rate
zoliflodacin (NUZOLVENCE) FDA approval for uncomplicated urogenital gonorrhea: 90.9% microbiologic cure vs 96.2% with ceftriaxone+azithromycin in Trial 1
Infectious Disease
FDA Approves IDVYNSO for Suppressed HIV-1: 1% ≥50 copies/mL
IDVYNSO (doravirine/islatravir) FDA approval for virologically suppressed HIV-1; 1% with HIV-1 RNA ≥50 copies/mL at Week 48 in pivotal trials. doravirine islatravir HIV-1
Infectious Disease
FDA Approves Ensitrelvir for COVID-19 Postexposure Prophylaxis: 67% Reduction in SCORPIO-PEP
Ensitrelvir (XOCOVA) FDA approval for COVID-19 post-exposure prophylaxis: 67% reduction in symptomatic infection in SCORPIO-PEP (adults/adolescents 12+).
Infectious Disease
WHO's 2026 Guidelines: A Comprehensive Approach to Combatting Antimicrobial Resistance
Explore WHO's 2026 guidelines on antimicrobial resistance, focusing on surveillance, infection control, and research investment.
Medical Research
Improve Ovarian Cancer Detection with Personalized Risk Score
Enhance patient outcomes with a cost-effective tool that combines blood test results and age for accurate ovarian cancer detection in women over 50.
Digital Health
Automate 90% of Intake Workflows with AI
Discover how AI-powered automation can streamline post-acute care workflows, freeing staff to focus on patient care and reducing administrative burdens.
Medical Research
Plant-Based Diet Cuts Type 2 Diabetes Risk
Discover how a plant-based diet can lower type 2 diabetes risk while reducing greenhouse gas emissions, benefiting both human and planetary health.
Digital Health
Stay Ahead with Daily Digital Health Updates
Get the latest digital health news, trends, and insights to enhance patient care and stay informed about industry developments and innovations.
Medical Research
Reuse Patient Studies to Cut Drug Dev Costs
Discover how reusing existing patient preference studies can optimize resource allocation and streamline drug development processes, reducing costs and improving efficiency.